Halda Therapeutics is a biotechnology company focused on discovering and developing small‑molecule, targeted therapies for cancer. The company’s approach centers on Regulated Induced Proximity Targeting Chimeras (RIPTACs), a class of bifunctional molecules designed to bring specific proteins into proximity within cancer cells to trigger selective cell killing.
Halda applies medicinal chemistry and structure‑guided design to create orally administered candidates intended to address solid tumors and overcome treatment resistance. Its pipeline is built around induced‑proximity mechanisms with the goal of expanding precision oncology options, and the underlying platform may enable future applications beyond oncology.